The Centers for Medicare & Medicaid Services Dec. 29 formally rescinded its Most Favored Nation model for Part B drugs. The model was established via interim final rule during the Trump administration to initiate a seven-year, nationwide, mandatory effort to test an alternative way for Medicare to pay for certain Medicare Part B single-source drugs and biologicals. CMS in August signaled its intent to end the model, for which AHA voiced support in an Oct. 11 letter to the agency by arguing that the rule’s “legal infirmities fell within three major categories: (1) failure to follow proper procedures in promulgating the rule, (2) exceeding statutory authority, and (3) constitutional violations.”

Related News Articles

Headline
The administration yesterday issued an interim final rule requiring health plans to begin submitting annual information next year on prescription drug…
Headline
In addition to being based on a very small sample size, a recently published study on hospital costs for clinician-administered drugs under Medicare Part B…
Blog
The authors of a recent analysis published in JAMA themselves acknowledge that their sample size is very small, making it hard to draw any sweeping conclusions…
Headline
The AHA today restated its strong support for the Centers for Medicare & Medicaid Services’ withdrawal of its Most Favored Nation Model proposed rule. In…
Headline
A new report released today by the Department of Health and Human Services outlines the Biden Administration’s plans to address high drug prices. The…
Headline
President Biden today urged Congress to allow Medicare to negotiate prescription drug prices and cap the amount beneficiaries pay out-of-pocket for drugs each…